145 related articles for article (PubMed ID: 6764096)
1. [Lymphokines].
Okuno K; Hamaoka T
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2053-64. PubMed ID: 6764096
[TBL] [Abstract][Full Text] [Related]
2. Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation.
Bertagnolli MM; Herrmann SH; Pinto VM; Schoof DD; Eberlein TJ
Surgery; 1991 Sep; 110(3):459-68. PubMed ID: 1887370
[TBL] [Abstract][Full Text] [Related]
3. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
Habib T; Nelson A; Kaushansky K
J Allergy Clin Immunol; 2003 Dec; 112(6):1033-45. PubMed ID: 14657853
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
5. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression.
Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN
Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959
[TBL] [Abstract][Full Text] [Related]
6. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
7. A human-mouse T-cell hybridoma-derived lymphokine inhibits thymidine uptake of T-lymphocytes.
Laus R; Müller-Ruchholtz W
Transplant Proc; 1989 Feb; 21(1 Pt 1):96-7. PubMed ID: 2784914
[No Abstract] [Full Text] [Related]
8. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
9. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
Dosne Pasqualini C; Laguens RP
Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
[No Abstract] [Full Text] [Related]
10. Innate immune recognition and suppression of tumors.
Hayakawa Y; Smyth MJ
Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta 1 enhances the generation of allospecific cytotoxic T lymphocytes.
Kondo S; Isobe K; Ishiguro N; Nakashima I; Miura T
Immunology; 1993 Jul; 79(3):459-64. PubMed ID: 8406573
[TBL] [Abstract][Full Text] [Related]
12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
15. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
17. Effects of ex vivo activated immune cells on syngeneic and semi-allogeneic bone marrow transplantation in mice.
Yang G; Tan J; Wei G; Deng Y; Chen H; Yang D
Transpl Immunol; 2006 Nov; 16(3-4):166-71. PubMed ID: 17138049
[TBL] [Abstract][Full Text] [Related]
18. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
19. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-dependent proliferation of T-lymphoid cells: regulated responsiveness and role in vivo.
Boothby M; Mora AL; Stephenson LM
Crit Rev Immunol; 2001; 21(6):487-522. PubMed ID: 12058862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
